Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3132-3139

  Lugade, Amit A ^a   Sorensen, Elizabeth W ^a   Gerber, Scott A ^a   Moran, James P ^a   Frelinger, John G ^a   Lord, Edith M ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Department of Microbiology and Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE MIG; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; HLA ANTIGEN CLASS 1;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL INFILTRATION; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; IMMUNE RESPONSE; IMMUNITY; IMPLANTATION; IN VIVO STUDY; IRRADIATION; MELANOMA B16; MELANOMA CELL; MICROENVIRONMENT; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; T LYMPHOCYTE; TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL MOTION; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; GAMMA RADIATION; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; GAMMA RAYS; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 45449090985     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3132     Document Type: Article

References (54)

1. Mukai, S., J. Kjaergaard, S. Shu, and G. E. Plautz. 1999. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59: 5245-5249.
2. + tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon γ plus tumor necrosis factor α. Cancer Immunol. Immunother. 38: 9-15.
3. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
4. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
5. Demaria, S., N. Bhardwaj, W. H. McBride, and S. C. Formenti. 2005. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63: 655-666.
6. McBride, W. H., C. S. Chiang, J. L. Olson, C. C. Wang, J. H. Hong, F. Pajonk, G. J. Dougherty, K. S. Iwamoto, M. Pervan, and Y. P. Liao. 2004. A sense of danger from radiation. Radiat. Res. 162: 1-19.
7. Blankenstein, T., and Z. Qin. 2003. The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154.
8. Dobrzanski, M. J., J. B. Reome, and R. W. Dutton. 2001. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98: 70-84.
9. McAdam, A. J., B. A. Pulaski, S. S. Harkins, E. K. Hutter, E. M. Lord, and J. G. Frelinger. 1995. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-γ on generation of murine tumor-reactive cytotoxic cells. Int. J. Cancer 61: 628-634.
10. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15: 749-795.
11. Fulda, S., and K. M. Debatin. 2002. IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295-2308.
12. Naldini, A., and F. Carraro. 2005. Role of inflammatory mediators in angiogenesis. Curr. Drug Targets Inflamm. Allergy 4: 3-8.
13. Dominiecki, M. E., G. L. Beatty, Z. K. Pan, P. Neeson, and Y. Paterson. 2005. Tumor sensitivity to IFN-γ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol. Immunother. 54: 477-488.
14. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFN γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9: 25-34.
15. Brown, D. M., T. L. Fisher, C. Wei, J. G. Frelinger, and E. M. Lord. 2001. Tumours can act as adjuvants for humoral immunity. Immunology 102: 486-497.
16. Beatty, G. L., and Y. Paterson. 2001. Regulation of tumor growth by IFN-γ in cancer immunotherapy. Immunol. Res. 24: 201-210.
17. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516-7523.
18. Blieden, T. M., A. J. McAdam, J. G. Frelinger, and E. M. Lord. 1991. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J. Immunol. 147: 1433-1438.
19. Cangemi, G., B. Morandi, A. D'Agostino, C. Peri, R. Conte, G. Damonte, G. Ferlazzo, R. Biassoni, and G. Melioli. 2003. IFN-α mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome. Int. Immunol. 15: 1415-1421.
20. Curfs, J. H., J. F. Meis, and J. A. Hoogkamp-Korstanje. 1997. A primer on cytokines: sources, receptors, effects, and inducers. Clin. Microbiol. Rev. 10: 742-780.
21. Gessani, S., and F. Belardelli. 1998. IFN-γ expression in macrophages and its possible biological significance. Cytokine Growth Factor Rev. 9: 117-123.
22. Nance, S., R. Cross, A. K. Yi, and E. A. Fitzpatrick. 2005. IFN-γ production by innate immune cells is sufficient for development of hypersensitivity pneumonitis. Eur. J. Immunol. 35: 1928-1938.
23. Palmer, K., M. Hitt, P. C. Emtage, S. Gyorffy, and J. Gauldie. 2001. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8: 282-290.
24. Moran, J. P., S. A. Gerber, C. A. Martin, J. G. Frelinger, and E. M. Lord. 2003. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int. J. Cancer 106: 690-698.
25. Abdel-Wahab, Z., M. M. Dar, D. Hester, C. Vervaert, R. Gangavalli, J. Barber, T. L. Darrow, and H. F. Seigler. 1996. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-γ gene-modified melanoma cells. Cell. Immunol. 171: 246-254.
26. Woods, M. L., A. J. McAdam, J. G. Frelinger, and E. M. Lord. 1993. Isolation and expansion of tumor-infiltrating lymphocytes. BioTechniques 15: 970-972.
27. Chin, Y. E., M. Kitagawa, K. Kuida, R. A. Flavell, and X. Y. Fu. 1997. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17: 5328-5337.
28. Svane, I. M., A. M. Engel, M. Nielsen, and O. Werdelin. 1997. Interferon-γ-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas. Scand. J. Immunol. 46: 379-387.
29. Platanias, L. C. 2005. Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat. Rev. Immunol. 5: 375-386.
30. Ganss, R., and D. Hanahan. 1998. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58: 4673-4681.
31. Barcellos-Hoff, M. H., C. Park, and E. G. Wright. 2005. Radiation and the microenvironment: tumorigenesis and therapy. Nat. Rev. Cancer 5: 867-875.
32. Ryschich, E., J. Schmidt, G. J. Hammerling, E. Klar, and R. Ganss. 2002. Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 97: 719-725.
33. Carlos, T. M. 2001. Leukocyte recruitment at sites of tumor: dissonant orchestration. J. Leukocyte Biol. 70: 171-184.
34. Hallahan, D., J. Kuchibhotla, and C. Wyble. 1996. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 56: 5150-5155.
35. Schnyder, B., S. Schnyder-Candrian, A. Pansky, M. L. Schmitz, M. Heim, B. Ryffel, and R. Moser. 2005. IL-17 reduces TNF-induced Rantes and VCAM-1 expression. Cytokine 31: 191-202.
36. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-1132.
37. Campbell, J. J., and E. C. Butcher. 2000. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol. 12: 336-341.
38. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550.
39. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754.
40. Yang, J., and A. Richmond. 2004. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9: 846-855.
41. Dufour, J. H., M. Dziejman, M. T. Liu, J. H. Leung, T. E. Lane, and A. D. Luster. 2002. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168: 3195-3204.
42. Strieter, R. M., P. J. Polverini, D. A. Arenberg, and S. L. Kunkel. 1995. The role of CXC chemokines as regulators of angiogenesis. Shock 4: 155-160.
43. Duguay, D., F. Mercier, J. Stagg, D. Martineau, J. Bramson, M. Servant, R. Lin, J. Galipeau, and J. Hiscott. 2002. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 62: 5148-5152.
44. Hatina, J., P. Jansa, and J. Reischig. 2002. Transcription factor NF-IL6 (C/EBPβ) activates the expression of the mouse MHC class I H2-Kb gene in response to TNF-α via the intragenic downstream regulatory element. J. Interferon Cytokine Res. 22: 741-749.
45. Brucet, M., L. Marques, C. Sebastian, J. Lloberas, and A. Celada. 2004. Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon γ is mediated by STAT1 and IRF-1. Genes Immun. 5: 26-35.
46. Min, W., J. S. Pober, and D. R. Johnson. 1996. Kinetically coordinated induction of TAP1 and HLA class I by IFN-γ: the rapid induction of TAP1 by IFN-γ is mediated by Stat1 α. J. Immunol. 156: 3174-3183.
47. Ramana, C. V., M. P. Gil, R. D. Schreiber, and G. R. Stark. 2002. Stat1-dependent and -independent pathways in IFN-γ-dependent signaling. Trends Immunol. 23: 96-101.
48. Kalai, M., M. Lamkanfi, G. Denecker, M. Boogmans, S. Lippens, A. Meeus, W. Declercq, and P. Vandenabeele. 2003. Regulation of the expression and processing of caspase-12. J. Cell Biol. 162: 457-467.
49. Liu, K., and S. I. Abrams. 2003. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-γ. J. Immunol. 170: 6329-6337.
50. Huang, S., C. D. Bucana, M. Van Arsdall, and I. J. Fidler. 2002. Stat1 negatively regulates angiogenesis, tumorigenicity, and metastasis of tumor cells. Oncogene 21: 2504-2512.
51. de Prati, A. C., A. R. Ciampa, E. Cavalieri, R. Zaffini, E. Darra, M. Menegazzi, H. Suzuki, and S. Mariotto. 2005. STAT1 as a new molecular target of antiinflammatory treatment. Curr. Med. Chem. 12: 1819-1828.
52. Turkson, J. 2004. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8: 409-422.
53. Abril, E., L. M. Real, A. Serrano, P. Jimenez, A. Garcia, J. Canton, I. Trigo, F. Garrido, and F. Ruiz-Cabello. 1998. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol. Immunother. 47: 113-120.
54. Khodarev, N. N., M. Beckett, E. Labay, T. Darga, B. Roizman, and R. R. Weichselbaum. 2004. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl. Acad. Sci. USA 101: 1714-1719.